Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Q2 EARNINGS: Thoratec slashes guidance as sales shrink

This article was originally published in Clinica

Executive Summary

Left ventricular assist device (LVAD) market leader Thoratec admitted being disappointed in its second-quarter results, as both its top and bottom line shrank. Revenues fell 10% to $118.1m, with sales of the firm’s flagship HeartMate device down 12% to $102.0m. Thoratec looks to be losing market share to number-two player HeartWare International, which recently posted a 38% jump in sales in Q2 as it saw increasing uptake of its rival HVAD device. The former has also not been helped by a study published in the NEJM last year last year linking its HeartMate II pump with an increased risk of blood clots.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT101823

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel